XRCC1 rs25487 多态性预测乳腺癌术后放化疗患者的生存。
XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.
机构信息
Cancer Center, Kuopio University Hospital, Kuopio, Finland Institute of Clinical Medicine, Pathology, University of Eastern Finland, Kuopio, Finland Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland
Institute of Clinical Medicine, Pathology, University of Eastern Finland, Kuopio, Finland Biocenter Kuopio, University of Eastern Finland, Kuopio, Finland Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland Imaging Center, Pathology, Kuopio University Hospital, Kuopio, Finland.
出版信息
Anticancer Res. 2014 Jun;34(6):3031-7.
BACKGROUND
Single nucleotide polymorphisms (SNPs) in a DNA-repair gene, X-Ray repair cross complementing group 1 (XRCC1), have been associated with the survival of patients with breast cancer. We investigated the predictive value of XRCC1 SNP (rs25487) in patients with early breast cancer.
PATIENTS AND METHODS
The XRCC1 rs25487 genotypes of 411 Finnish patients with breast cancer were analyzed by a polymerase chain reaction-restriction fragment length polymorphism-based method. Survival was assessed by Kaplan-Meier method and Cox regression analysis according to the XRCC1 genotypes in specified adjuvant treatment groups.
RESULTS
The rs25487 variant AA genotype was associated with worse breast cancer-specific and overall survival in 238 patients receiving postoperative radiotherapy (p=0.031 and p=0.030, respectively). The AA genotype predicted worse breast cancer-specific survival among 75 patients treated with adjuvant chemotherapy (p=0.047).
CONCLUSION
The XRCC1 rs25487 genotype may predict the outcome of postoperative radiotherapy and adjuvant chemotherapy in breast cancer.
背景
DNA 修复基因 X 射线修复交叉互补组 1（XRCC1）中的单核苷酸多态性（SNPs）与乳腺癌患者的生存有关。我们研究了 XRCC1 SNP（rs25487）在早期乳腺癌患者中的预测价值。
患者和方法
通过聚合酶链反应-限制性片段长度多态性方法分析了 411 例芬兰乳腺癌患者的 XRCC1 rs25487 基因型。根据特定辅助治疗组中的 XRCC1 基因型，通过 Kaplan-Meier 方法和 Cox 回归分析评估生存情况。
结果
在接受术后放疗的 238 例患者中，rs25487 变异 AA 基因型与乳腺癌特异性和总体生存率较差相关（p=0.031 和 p=0.030）。在接受辅助化疗的 75 例患者中，AA 基因型预测乳腺癌特异性生存率较差（p=0.047）。
结论
XRCC1 rs25487 基因型可能预测乳腺癌术后放疗和辅助化疗的结果。
Zotero 插件